<SEC-DOCUMENT>0001193125-23-014323.txt : 20230124
<SEC-HEADER>0001193125-23-014323.hdr.sgml : 20230124
<ACCEPTANCE-DATETIME>20230124171319
ACCESSION NUMBER:		0001193125-23-014323
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20230124
DATE AS OF CHANGE:		20230124

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KOPIN CORP
		CENTRAL INDEX KEY:			0000771266
		STANDARD INDUSTRIAL CLASSIFICATION:	SEMICONDUCTORS & RELATED DEVICES [3674]
		IRS NUMBER:				042833935
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1225

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-253933
		FILM NUMBER:		23548984

	BUSINESS ADDRESS:	
		STREET 1:		125 NORTH DRIVE
		CITY:			WESTBOROUGH
		STATE:			MA
		ZIP:			01581
		BUSINESS PHONE:		508-870-5959

	MAIL ADDRESS:	
		STREET 1:		125 NORTH DRIVE
		CITY:			WESTBOROUGH
		STATE:			MA
		ZIP:			01581
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d386798d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed pursuant to Rule 424(b)(5)<BR>Registration Number: 333-253933 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Arial Narrow"><FONT COLOR="#ff4338"><B>The information in this preliminary prospectus supplement is not
complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are part of an effective registration statement filed with the Securities and Exchange Commission under the Securities Act of 1933. This preliminary
prospectus supplement and the accompanying prospectus are not an offer to sell these securities, nor are they soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted. </B></FONT></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>Subject to completion, dated January 24, 2023
</B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preliminary Prospectus Supplement </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(to
Prospectus dated April&nbsp;27, 2022) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g386798g43k01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>Kopin Corporation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Shares of Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Pre-Funded Warrants to Purchase&nbsp;&nbsp;&nbsp;&nbsp;Shares of Common Stock </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are offering&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock and, in lieu of
common stock, <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock pursuant to this prospectus supplement
and the accompanying prospectus. The purchase price of each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant equals the price per share at which shares of our common stock are being sold to the public in this offering, minus $0.01, and the
exercise price of each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant equals $0.01 per share. This prospectus supplement also relates to the offering of the shares of common stock issuable upon exercise of such <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Capital Market under the symbol &#147;KOPN.&#148; On
January&nbsp;23, 2023, the last reported sale price of our common stock on the Nasdaq Capital Market was $1.27 per share. We do not intend to list the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on the Nasdaq, any other national
securities exchange or any other nationally recognized trading system. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities
involves risks. You should review carefully the risks and uncertainties described under the heading &#147;<A HREF="#supptx433739_5">Risk Factors</A>&#148; on page <FONT STYLE="white-space:nowrap">S-6</FONT> of this prospectus supplement and under
similar headings in the other documents that are incorporated by reference in this prospectus supplement and the accompanying prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to
the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per<BR><FONT STYLE="white-space:nowrap">Pre-Funded</FONT><BR>Warrant</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds to us, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We have also agreed to reimburse the underwriters for certain of their expenses. See &#147;Underwriting&#148;
beginning on page S-10 of this prospectus supplement for more information about these arrangements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have granted the underwriters
the right to purchase up to an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of our common stock at a price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. The underwriters may exercise this right at any time, in whole or in part, within 30 days following the date of this prospectus supplement.
If the underwriters exercise the option in full, the total underwriting discount payable by us will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and the total proceeds to us, before expenses,
will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We anticipate that delivery of the common
stock and pre-funded warrants against payment will be made on or about January&nbsp;&nbsp;&nbsp;&nbsp;, 2023. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Stifel
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is January&nbsp;&nbsp;&nbsp;&nbsp;, 2023. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>PROSPECTUS SUPPLEMENT </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx433739_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx433739_2">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx433739_3">PROSPECTUS SUPPLEMENT SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx433739_4">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx433739_5">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx433739_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx433739_7">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-9</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc386798_7a">DESCRIPTION OF <FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANTS
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-11</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx433739_8">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-13</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx433739_9">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-20</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx433739_10">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-20</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx433739_11">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-20</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx433739_12">INCORPORATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-20</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B><U>PROSPECTUS</U></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx433739_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx433739_2">THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx433739_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx433739_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx433739_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx433739_6">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx433739_7">GENERAL DESCRIPTION OF SECURITIES THAT WE MAY SELL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx433739_8">DESCRIPTION OF OUR COMMON STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx433739_9">DESCRIPTION OF OUR PREFERRED STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx433739_10">DESCRIPTION OF OUR WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx433739_11">DESCRIPTION OF OUR DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx433739_12">WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY
REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx433739_13">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx433739_14">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-i- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx433739_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus, dated April&nbsp;27, 2022, are part of a &#147;shelf&#148; registration statement
on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-253933).</FONT> This document is in two parts. The first part is this prospectus supplement, which describes the terms of this offering of shares
of our common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement and the
accompanying prospectus. The second part, the accompanying prospectus, including the documents incorporated by reference, provides more general information, some of which may not apply to this offering. Generally, when we refer to this prospectus,
we are referring to both parts of this document combined. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or in any
document incorporated by reference that was filed with the Securities and Exchange Commission, or SEC, before the date of this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement. If any
statement in one of these documents is inconsistent with a statement in another document having a later date, the statement in the document having the later date modifies or supersedes the earlier statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in, or incorporated by reference into, this prospectus supplement and the accompanying
prospectus. We have not authorized anyone to provide you with different or additional information. You should assume that the information in this prospectus supplement and the accompanying prospectus is accurate only as of the date on the front of
the respective document and that any information that we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus supplement or the accompanying
prospectus or the time of any sale of a security. Our business, financial condition, results of operations and prospects may have changed since those dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this prospectus supplement, the terms the &#147;Company,&#148; &#147;Kopin,&#148; &#147;we,&#148; &#147;our&#148; and
&#147;us&#148; or other similar terms mean Kopin Corporation and its subsidiaries, unless the context indicates otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
prospectus supplement, the accompanying prospectus and the information incorporated by reference herein and therein include trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names
included or incorporated by reference into this prospectus supplement or the accompanying prospectus are the property of their respective owners. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx433739_2"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the other documents we have filed with the SEC that are incorporated herein by reference contain
forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. Words such as &#147;expects,&#148; &#147;anticipates,&#148; &#147;intends,&#148;
&#147;plans,&#148; &#147;believes,&#148; &#147;could,&#148; &#147;would,&#148; &#147;potential,&#148; &#147;seeks,&#148; &#147;estimates,&#148; and variations of such words and similar expressions are intended to identify such forward-looking
statements. These statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or
forecasted in such forward-looking statements, whether as a result of new information, future events or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have identified the
following important factors that could cause actual results to differ materially from those discussed in our forward-looking statements. Such factors may be in addition to the risks described in Part I, Item 1A, &#147;Risk Factors;&#148; Part II,
Item 7. Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations; and other parts of our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;25, 2021 (the
&#147;2021 Form 10-K&#148;). These factors include: our ability to source semiconductor components and other raw materials used in the manufacturing of our products amidst continued intermittent shortages, including from new and alternative
suppliers; our ability to prosecute and defend our proprietary technology aggressively or successfully; our ability to retain personnel with experience and expertise relevant to our business; our ability to invest in research and development to
achieve profitability even during periods when we are not profitable; our ability to continue to introduce new products in our target markets; our ability to generate revenue growth and positive cash flow, and reach profitability; the strengthening
of the U.S. dollar and its effects on the price of our products in foreign markets; the impact of new regulations and customer demands relating to conflict minerals; our ability to grow within our targeted markets; the importance of small form
factor displays in the development of defense, consumer, and industrial products such as thermal weapon sights, safety equipment, virtual and augmented reality gaming, training and simulation products and metrology tools; the suitability of our
properties for our needs for the foreseeable future; our expectation not to pay cash dividends for the foreseeable future and to retain earnings for the development of our businesses; our need to achieve and maintain positive cash flow and
profitability, and our expectation that if we do not achieve and maintain positive cash flow and profitability, our financial condition will ultimately be materially adversely affected, and we will be required to reduce expenses, including our
investments in research and development or raise additional capital and our ability to support our operations and capital needs for at least the next twelve months through our available cash resources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as required by the federal securities laws, we do not intend to update any forward-looking statements even if new information becomes
available or other events occur in the future. You should read this prospectus supplement and the documents that we incorporate by reference into this prospectus supplement completely and with the understanding that our actual future results may be
materially different from what we expect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx433739_3"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights certain information about us, this offering and information appearing elsewhere in this prospectus supplement and in the
accompanying prospectus and in the documents we incorporate by reference. This summary is not complete and does not contain all of the information that you should consider before investing in shares of our common stock. The following summary is
qualified in its entirety by, and should be read in conjunction with, the more detailed information appearing elsewhere in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein. Before
you decide to invest in shares of our common stock, to fully understand this offering and its consequences to you, you should read the entire prospectus supplement and the accompanying prospectus carefully, including the risk factors beginning on
page <FONT STYLE="white-space:nowrap">S-6</FONT> of this prospectus supplement and the documents incorporated by reference herein and therein. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a leading developer,
manufacturer and seller of application specific optical assemblies which are composed of our miniature displays and optical lenses (our &#147;components&#148;) for sale as individual displays, components, modules, or higher-level subassemblies. We
also license our intellectual property through technology license agreements. Our component products are used in highly demanding high-resolution portable military, commercial and consumer electronic applications, training and simulation equipment
and 3D metrology equipment. Our products enable our customers to develop and market an improved generation of products for these target applications. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preliminary Estimated Unaudited
Financial Results for the Fiscal Quarter Ended December&nbsp;31, 2022 </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our preliminary estimated unaudited total revenues for the
fiscal quarter ended December&nbsp;31, 2022 are expected to be between $11.0 and $11.5&nbsp;million. We have provided a range for these preliminary financial results because our closing procedures for our fiscal quarter and fiscal year ended
December&nbsp;31, 2022 are not yet complete. Our preliminary estimates of these financial results are based solely on information available to us as of the date of this prospectus and are inherently uncertain and subject to change. Our actual
results remain subject to the completion of management&#146;s final review and our other closing procedures, as well as the completion of the audit of our annual consolidated financial statements. These preliminary estimates are not a comprehensive
statement of our financial results for the three-month period and the fiscal year ended December&nbsp;31, 2022 and should not be viewed as a substitute for full financial statements prepared in accordance with GAAP. In addition, these preliminary
estimates for the fiscal quarter ended December&nbsp;31, 2022 are not necessarily indicative of the results to be achieved in any future period. Accordingly, you should not place undue reliance on these preliminary financial results. See &#147;Risk
Factors&#148; and &#147;Special Note Regarding Forward-Looking Statements&#148; for a discussion of certain factors that could result in differences between the preliminary estimated unaudited financial results reported above and the actual results.
Our actual audited consolidated financial statements and related notes as of and for the fiscal year ended December&nbsp;31, 2022 are not expected to be filed with the SEC until after the completion of this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restructuring and Partial Spinout of OLED Development Unit </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;5, 2023, we announced that we had entered into a Technology License Agreement (the &#147;LS Agreement&#148;) with Lightning
Silicon Technology, Inc. (&#147;Lightning Silicon&#148;), a California company. Lightning Silicon is a company formed by Dr.&nbsp;John&nbsp;C.C. Fan, our Chairman of the Board, and former Chief Executive
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Officer, to develop and supply advanced organic light emitting diode (&#147;OLED&#148;) microdisplays for the consumer augmented reality and virtual reality markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the LS Agreement, Lightning Silicon received a license to certain Kopin intellectual property to develop, manufacture and
sell OLED technologies for use in the consumer market. We received an equity interest in Lightning Silicon and expect to receive royalties from the sale of products related to the licenses. We retained the ability and rights to develop, manufacture
and sell OLED displays and complete optical solutions that include microdisplays to our core base in the defense and enterprise markets, as well as value added consumer applications. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were
incorporated in Delaware in 1984. The mailing address of our principal executive offices is 125 North Drive Westborough, MA 01581. Our telephone number is (508) <FONT STYLE="white-space:nowrap">870-5959</FONT> and our website is www.kopin.com. The
information on our website or any other website is not incorporated by reference in this prospectus supplement and does not constitute a part of this prospectus supplement. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx433739_4"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Common stock offered by us:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Public offering price:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Common stock to be outstanding immediately after this offering:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Pre-funded warrants offered:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">We are also offering, in lieu of common stock, pre-funded warrants to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock. The purchase price of each pre-funded warrant will
equal the price per share at which the shares of our common stock are being sold to the public in this offering, minus $0.01, and the exercise price of each pre-funded warrant is $0.01 per share. Each pre-funded warrant will be exercisable at any
time after the date of issuance, subject to an ownership limitation. See &#147;Description of Pre-Funded Warrants.&#148; This prospectus supplement also relates to the offering of the shares of our common stock issuable upon exercise of the
pre-funded warrants.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Option to purchase additional shares:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">We have granted to the underwriters an option, exercisable within 30 days from the date of this prospectus supplement, to purchase up to an additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of
common stock to be offered by us pursuant to this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Use of proceeds:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">We currently intend to use the net proceeds of this offering for working capital and general corporate purposes. See &#147;Use of Proceeds.&#148;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Risk Factors:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Investing in our securities involves a high degree of risk. See &#147;<A HREF="#supptx433739_5">Risk Factors</A>&#148; beginning on <FONT STYLE="white-space:nowrap">page&nbsp;S-6</FONT> of this prospectus supplement and the other
information included or incorporated by reference in this prospectus supplement and the accompanying prospectus.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">The Nasdaq Capital Market symbol:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#147;KOPN.&#148;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table above is based on 95,107,358 shares of our common stock outstanding and issued as of
September&nbsp;24, 2022, which excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6,956,368&nbsp;shares of common stock available for future issuance under our equity incentive plan; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon the
exercise of the pre-funded warrants offered hereby. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, all information in this prospectus
supplement assumes no exercise by the underwriters of their option to purchase additional shares of common stock and no exercise of the pre-funded warrants. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx433739_5"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing in our securities involves a high degree of risk. For a discussion of the factors you should carefully consider before deciding to purchase any
of our securities, please review &#147;Part I, Item 1.A Risk Factors&#148; in our 2021 Form <FONT STYLE="white-space:nowrap">10-K</FONT> and &#147;Part II, Item 1.A Risk Factors&#148; in our Quarterly Report on Form 10-Q for the fiscal quarter ended
September 24, 2022, which is incorporated by reference in this prospectus supplement and the accompanying prospectus in its entirety, together with the other information contained in this prospectus supplement, the accompanying prospectus and the
documents we have filed or will subsequently file that are incorporated by reference. The risks and uncertainties described in the documents incorporated by reference are not the only risks and uncertainties we face. Additional risks and
uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. If any of those risks actually occur, our business, financial condition and results of operations could suffer. In that event, the
market price of our common stock could decline, and you may lose all or part of your investment in our securities. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to this Offering
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our management will have broad discretion over the use of the net proceeds from this offering, you may not agree with how we use the proceeds,
and the proceeds may not be invested successfully. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion as to the use of the net proceeds
from any offering by us and could use them for purposes other than those contemplated at the time of this offering. Accordingly, you will be relying on the judgment of our management with regard to the use of these net proceeds, and you will not
have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that the proceeds will be invested in a way that does not yield a favorable, or any, return for us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may experience immediate and substantial dilution in the book value per share of the common stock you purchase in the offering. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offering price per share in this offering is higher than the net tangible book value per share of our common stock outstanding prior to
this offering. As such, you will suffer immediate substantial dilution in the net tangible book value per share of common stock from the public offering price per share of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Moreover, the exercise of outstanding stock options or the pre-funded warrants offered hereby will result in further dilution of your investment. See
the section below entitled &#147;Dilution&#148; for a more detailed illustration of the dilution you would incur if you participate in this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will require additional capital funding, the receipt of which may impair the value of our common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future capital requirements depend on many factors, including our research, development, sales and marketing activities. We may need to
raise additional capital through public or private equity or debt offerings or through arrangements with strategic partners or other sources in order to continue to develop our products. There can be no assurance that additional capital will be
available when needed or on terms satisfactory to us, if at all. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution and the new equity securities may have greater rights,
preferences or privileges than our existing common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our history of net operating losses and our accumulated deficit raise substantial doubt
regarding our ability to continue as a going concern. If we do not continue as a going concern, investors could lose their entire investment. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our history of net operating losses, in addition to our significant accumulated deficit, has raised substantial doubt about our ability to
continue as a going concern. Our ability to continue as a going concern is dependent upon our becoming profitable in the future or to obtain the necessary capital to meet our obligations and repay </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our liabilities when they become due. Our determination of substantial doubt as going concern could materially limit our ability to raise additional funds through the issuance of equity
securities or otherwise. There can be no assurance that we will ever become profitable or continue as a going concern. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There is no public market
for the pre-funded warrants being offered in this offering. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no public trading market for the pre-funded warrants being
offered in this offering, and we do not expect a market to develop. In addition, we do not intend to apply to list the pre-funded warrants on any securities exchange or nationally recognized trading system, including the Nasdaq. Without an active
market, the liquidity of the pre-funded warrants will be limited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not receive any additional funds upon the exercise of the pre-funded
warrants. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each pre-funded warrant may be exercised by way of a cashless exercise, meaning that the holder may not pay a cash
purchase price upon exercise, but instead would receive upon such exercise the net number of shares of our common stock determined according to the formula set forth in the pre-funded warrant. Accordingly, we may not receive any additional funds
upon the exercise of the pre-funded warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Holders of pre-funded warrants purchased in this offering will have no rights as holders of our
common stock with respect to the shares underlying such pre-funded warrants until such holders exercise their pre-funded warrants and acquire our common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until holders of pre-funded warrants acquire shares of our common stock upon exercise of the pre-funded warrants, holders of pre-funded
warrants will have no rights with respect to the shares of our common stock underlying such pre-funded warrants including with respect to dividends and voting rights. Upon exercise of the pre-funded warrants, the holders will be entitled to exercise
the rights of a holder of our common stock only as to matters for which the record date occurs after the exercise date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Significant holders or
beneficial holders of our common stock may not be permitted to exercise pre-funded warrants that they hold. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of a
pre-funded warrant will not be entitled to exercise any portion of any pre-funded warrant which, upon giving effect to such exercise, would cause (i) the aggregate number of shares of our common stock beneficially owned by the holder (together with
its affiliates) to exceed 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, or (ii) the combined voting power of our securities beneficially owned by the holder (together with its
affiliates) to exceed 9.99% of the combined voting power of all of our securities then outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the pre-funded warrants.
As a result, you may not be able to exercise your pre-funded warrants for shares of our common stock at a time when it would be financially beneficial for you to do so. In such circumstance you could seek to sell your pre-funded warrants to realize
value, but you may be unable to do so in the absence of an established trading market for the pre-funded warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx433739_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds of this offering, after deducting underwriting discounts and commissions and the other estimated offering
expenses payable by us, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise their option to purchase additional shares. We will receive nominal proceeds, if any, upon exercise of the
pre-funded warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently intend to use the net proceeds of this offering for working capital and general corporate purposes.
While we have estimated the particular uses for the net proceeds of this offering, we have not determined the amounts we plan to spend on any of the areas listed above or the timing of these expenditures. As a result, our management will have broad
discretion to allocate the net proceeds from this offering for any purpose, and investors will be relying on the judgment of our management with regard to the use of these net proceeds. Pending use of the net proceeds as described above, we intend
to invest the net proceeds in money-market funds or U.S. treasuries until we use them for their stated purpose. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx433739_7"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our common stock, your interest will be diluted immediately to the extent of the difference between the public offering price
per share of our common stock and the as adjusted net tangible book value per share of common stock after this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net tangible
book value of our common stock as of September&nbsp;24, 2022, was approximately $30.2&nbsp;million, or approximately $0.32 per share. Net tangible book value per share represents the amount of our total tangible assets less total liabilities divided
by the total number of shares of our common stock outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors represents the difference between the
amount per share paid by purchasers for our common stock in this offering and the net tangible book value per share of our common stock immediately following the completion of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving effect to the sale of shares of common stock offered by this prospectus supplement at a public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and pre-funded warrants to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of
common stock at the public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per pre-funded warrant (which equals the public offering price per share of our common stock less the
$0.01 per share exercise price of each such pre-funded warrant) (and excluding shares of our common stock issued and any proceeds received upon exercise of the pre-funded warrants or any resulting accounting associated with the pre-funded warrants),
and after deducting commissions and estimated aggregate offering expenses payable by us, our as adjusted net tangible book value as of September&nbsp;24, 2022 would have been approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. This represents an
immediate increase in net tangible book value of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to our existing stockholders and an immediate dilution in as adjusted net
tangible book value of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to purchasers of our common stock in this offering, as illustrated by the following table: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per share at September&nbsp;24, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share attributable to investors purchasing our common
stock in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per share as of September&nbsp;24, 2022 after giving effect to
this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to investors purchasing our common stock in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise in full their option to purchase additional shares of our common stock, our as
adjusted net tangible book value as of September&nbsp;24, 2022 would have been approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. This represents an immediate increase in as adjusted net tangible book value per share of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to existing stockholders, and an immediate dilution of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to investors participating in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If holders of pre-funded warrants exercise the pre-funded warrants in full, the as adjusted net tangible book value per share of common stock
after giving effect to this offering (but not the exercise of the underwriters&#146; option to purchase additional shares) would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, and the
dilution in net tangible book value per share to investors purchasing common stock in this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table above is based on 95,107,358 shares of our common stock outstanding and issued as of September&nbsp;24, 2022, which excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6,956,368 shares of common stock available for future issuance under our equity incentive plan; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common
stock issuable upon the exercise of the pre-funded warrants offered hereby. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that outstanding options are exercised, you will experience further dilution.
In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised
through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc386798_7a"></A>DESCRIPTION OF PRE-FUNDED WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a brief summary of certain terms and conditions of the pre-funded warrants being offered by us. The following description is
subject in all respects to the provisions contained in the pre-funded warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pre-funded warrants will be issued as individual warrant agreements to each individual purchaser of a warrant. The form of pre-funded
warrant will be filed as an exhibit to a Current Report on Form 8-K that we will file with the SEC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Term </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pre-funded warrants do not expire. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercisability </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pre-funded warrants
are exercisable at any time after their original issuance. The pre-funded warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice and by payment in full of the exercise
price in immediately available funds for the number of shares of our common stock purchased upon such exercise. As an alternative to payment of the exercise price in immediately available funds, the holder may elect to exercise the pre-funded
warrant through a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of our common stock determined according to the formula set forth in the pre-funded warrant. No fractional shares of our common
stock will be issued in connection with the exercise of a pre-funded warrant. In lieu of fractional shares, we will pay the holder an amount in cash equal to the fractional amount multiplied by the last closing trading price of our common stock on
the exercise date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercise Limitations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the pre-funded warrants, we may not effect the exercise of any pre-funded warrant, and a holder will not be entitled to exercise any
portion of any pre-funded warrant, which, upon giving effect to such exercise, would cause (i) the aggregate number of shares of our common stock beneficially owned by the holder (together with its affiliates) to exceed 9.99% of the number of shares
of our common stock outstanding immediately after giving effect to the exercise, or (ii) the combined voting power of our securities beneficially owned by the holder (together with its affiliates) to exceed 9.99% of the combined voting power of all
of our securities then outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the pre-funded warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercise Price </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exercise price per
whole share of our common stock issuable upon the exercise of the pre-funded warrants is $0.01 per share of our common stock. The exercise price of the pre-funded warrants and the number of shares of our common stock issuable upon exercise of the
pre-funded warrants is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock and also upon any distributions of
assets, including cash, stock or other property to our stockholders. The exercise price will not be adjusted below the par value of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transferability </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to applicable laws, the pre-funded warrants may be offered for sale, sold, transferred or assigned without our consent. The pre-funded
warrants will be held in definitive form by the purchasers. The ownership of the pre-funded warrants and any transfers of the pre-funded warrants will be registered in a warrant register maintained by us or our transfer agent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exchange Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not plan on
applying to list the pre-funded warrants on The Nasdaq Capital Market, any other national securities exchange or any other nationally recognized trading system. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fundamental Transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of
a fundamental transaction, as described in the pre-funded warrants and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our
properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our
outstanding common stock, upon consummation of such a fundamental transaction, the holders of the pre-funded warrants will be entitled to receive upon exercise of the pre-funded warrants the kind and amount of securities, cash or other property that
the holders would have received had they exercised the pre-funded warrants immediately prior to such fundamental transaction without regard to any limitations on exercise contained in the pre-funded warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Rights as a Stockholder </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except by
virtue of such holder&#146;s ownership of shares of our common stock, the holder of a pre-funded warrant does not have the rights or privileges of a holder of our common stock, including any voting rights or the rights to receive dividends, until
the holder exercises the pre-funded warrant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx433739_8"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stifel, Nicolaus&nbsp;&amp; Company, Incorporated is acting as the representative of the underwriters. Subject to the terms and conditions set
forth in an underwriting agreement dated the date of this prospectus supplement among us and the representative of the underwriters named below, we have agreed to sell to the underwriters, and each underwriter has severally agreed to purchase from
us, the number of shares of common stock and pre-funded warrants to purchase shares of common stock listed next to its name in the following table. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="28%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="28%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Number&nbsp;of&nbsp;Pre-Funded&nbsp;Warrants</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stifel, Nicolaus&nbsp;&amp; Company, Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters are committed to purchase all the shares of common stock and pre-funded warrants offered by
us if they purchase any shares. The underwriting agreement also provides that if an underwriter defaults, the purchase commitments of nondefaulting underwriters may be increased or the offering may be terminated. The underwriters are not obligated
to purchase the shares of common stock covered by the option to purchase additional shares described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters are offering
the shares of common stock and pre-funded warrants, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel, and other conditions contained in the underwriting agreement, such as
the receipt by the underwriters of officers&#146; certificates and legal opinions. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discounts and Commissions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
underwriters propose initially to offer the shares of common stock and pre-funded warrants to the public at the public offering price set forth on the cover page of this prospectus supplement and to dealers at that price less a concession not in
excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. After the initial offering of the shares, the public offering price and other selling terms may be changed by the representative.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the public offering price, underwriting discounts and commissions and proceeds before expenses to us. The
information assumes either no exercise or full exercise of the option we granted to the underwriters to purchase additional shares. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Per&nbsp;Pre-Funded</FONT><BR>Warrant</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and
commissions referred to above, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also agreed to reimburse the underwriters for legal and other expenses incurred by them in connection with this offering, up to
$75,000. In accordance with FINRA Rule 5110, the amount reimbursed to the underwriters is deemed underwriter compensation for this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option to
Purchase Additional Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus
supplement, to purchase, from time to time, in whole or in part, up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares from us at the </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
public offering price set forth on the cover page of this prospectus supplement, less underwriting discounts and commissions. If the underwriters exercise this option, each underwriter will be
obligated, subject to specified conditions, to purchase a number of additional shares proportionate to that underwriter&#146;s initial purchase commitment as indicated in the table above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our officers and directors have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters. Under
these agreements, we and these other individuals have agreed, subject to specified exceptions, for a period ending 90&nbsp;days after the date of this prospectus supplement, not to, without first obtaining the written consent of the representative,
offer, sell, contract to sell (including any short sale), pledge, hypothecate, establish an open &#147;put equivalent position&#148; within the meaning of Rule <FONT STYLE="white-space:nowrap">16a-1(h)</FONT> under the Exchange Act, grant any
option, right or warrant for the sale of, purchase any option or contract to sell, sell any option or contract to purchase, or otherwise encumber, dispose of or transfer, or grant any rights with respect to, directly or indirectly, any shares of
common stock or securities convertible into or exchangeable or exercisable for any shares of common stock, enter into a transaction that would have the same effect, or enter into any swap, hedge or other arrangement that transfers, in whole or in
part, any of the economic consequences of ownership of the common stock, whether any such aforementioned transaction is to be settled by delivery of the common stock or such other securities, in cash or otherwise, or publicly disclose the intention
to make any such offer, sale, pledge or disposition, or to enter into any such transaction, swap, hedge or other arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The lockup
restrictions are subject to certain exceptions. In the case of our officers and directors, these exceptions include (i)&nbsp;bona fide gifts; (ii)&nbsp;the exercise of any option or warrant to purchase shares of common stock outstanding on the date
of this prospectus supplement; (iii)&nbsp;the receipt of shares of common stock in payment of a portion of salary or the vesting of any restricted stock; or (iv)&nbsp;the entry into a trading plan pursuant to Rule
<FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act. The restrictions described above will not apply to the exercise of the pre-funded warrants during the 90-day period following the date of this prospectus supplement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to
indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the underwriters may be required to make for these liabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stabilization </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters have
advised us that they, pursuant to Regulation M under the Exchange Act, and certain persons participating in the offering may engage in short sale transactions, stabilizing transactions, syndicate covering transactions or the imposition of penalty
bids in connection with this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These activities may have the effect of stabilizing or maintaining the market price of the common
stock at a level above that which might otherwise prevail in the open market. Establishing short sales positions may involve either &#147;covered&#148; short sales or &#147;naked&#148; short sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Covered&#148; short sales are sales made in an amount not greater than the underwriters&#146; option to purchase additional shares of
our common stock in this offering. The underwriters may close out any covered short position by either exercising their option to purchase additional shares of our common stock or purchasing shares of our common stock in the open market. In
determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares
through the option to purchase additional shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Naked&#148; short sales are sales in excess of the option to purchase additional
shares of our common stock. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure
on the price of the shares of our common stock in the open market after pricing that could adversely affect investors who purchase in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A stabilizing bid is a bid for the purchase of shares of common stock on behalf of the underwriters for the purpose of fixing or maintaining
the price of the common stock. A syndicate covering transaction is the bid for or the purchase of shares of common stock on behalf of the underwriters to reduce a short position incurred by the underwriters in connection with the offering. Similar
to other purchase transactions, the underwriters&#146; purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our
common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. A penalty bid is an arrangement permitting the underwriters to reclaim the selling concession otherwise accruing to
a syndicate member in connection with the offering if the shares of common stock originally sold by such syndicate member are purchased in a syndicate covering transaction and therefore have not been effectively placed by such syndicate member. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the
transactions described above may have on the price of our common stock. The underwriters are not obligated to engage in these activities and, if commenced, any of the activities may be discontinued at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters may also engage in passive market making transactions in our common stock in accordance with Rule 103 of Regulation M during
a period before the commencement of offers or sales of shares of our common stock in this offering and extending through the completion of distribution. A passive market maker must display its bid at a price not in excess of the highest independent
bid of that security. However, if all independent bids are lowered below the passive market maker&#146;s bid, that bid must then be lowered when specified purchase limits are exceeded. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and
their respective affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal
investment, hedging, financing and brokerage activities. Certain of the underwriters and their respective affiliates have, from time to time, performed, and may in the future perform, various financial advisory and investment banking services for
us, for which they received or will receive customary fees and expenses. Stifel, Nicolaus&nbsp;&amp; Company, Incorporated is the sales agent under our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT>
equity offering program, pursuant to which it receives customary fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their various business
activities, the underwriters and their respective affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their
own account and for the accounts of their customers and may at any time hold long and short positions in such securities and instruments. Such investment and securities activities may involve our securities and instruments. The underwriters and
their respective affiliates may also make investment recommendations or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long or short
positions in such securities and instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Offer, Sale and Distribution of Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus supplement in electronic format may be made available on the websites maintained by one or more underwriters or selling group
members, if any, participating in the offering. The underwriters may agree to allocate a number of shares of common stock and pre-funded warrants to underwriters and selling group members for sale to their online brokerage account holders. Internet
distributions will be allocated by the representative to underwriters and selling group members that may make Internet distributions on the same basis as other allocations. Other than the prospectus supplement in electronic format, the information
on the underwriters&#146; websites and any information contained in any other website maintained by the underwriters is not part of this prospectus supplement or the registration statement of which this prospectus supplement forms a part. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Investors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities
offered by this prospectus supplement in any jurisdiction where action for that purpose is required. The securities offered by this prospectus supplement may not be offered or sold, directly or indirectly, nor may this prospectus supplement or any
other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and
regulations of that jurisdiction. Persons into whose possession this prospectus supplement comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus
supplement in any jurisdiction in which such an offer or a solicitation is unlawful. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling Restrictions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Canada</I>. The common stock and pre-funded warrants may be sold only to purchasers purchasing, or deemed to be purchasing, as principal
that are accredited investors, as defined in National <FONT STYLE="white-space:nowrap">Instrument&nbsp;45-106</FONT><I>&nbsp;Prospectus Exemptions</I>&nbsp;or subsection 73.3(1) of the<I>&nbsp;Securities Act</I><I></I>&nbsp;(Ontario), and are
permitted clients, as defined in National <FONT STYLE="white-space:nowrap">Instrument&nbsp;31-103</FONT><I>&nbsp;Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>. Any resale of the common stock and pre-funded warrants
must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this
prospectus supplement (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the
purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 of National <FONT STYLE="white-space:nowrap">Instrument&nbsp;33-105</FONT><I>&nbsp;Underwriting Conflicts</I><I></I><FONT
STYLE="white-space:nowrap">&nbsp;(NI&nbsp;33-105),&nbsp;the</FONT> underwriters are not required to comply with the disclosure requirements of <FONT STYLE="white-space:nowrap">NI&nbsp;33-105&nbsp;regarding</FONT> underwriter conflicts of interest in
connection with this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Switzerland.</I><I></I>&nbsp;The securities will not be offered, directly or indirectly, to the public
in Switzerland and this prospectus does not constitute a public offering prospectus as that term is understood pursuant to article 652a or 1156 of the Swiss Federal Code of Obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>European Economic Area and the United Kingdom.</I><I></I>&nbsp;In relation to each Member State of the European Economic Area and the
United Kingdom (each, a &#147;Member State&#148;), no shares have been offered or will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
offered pursuant to the offering to the public in that Member State prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in that
Member State or, where appropriate, approved in another Member State and notified to the competent authority in that Member State, all in accordance with the Prospectus Regulation, except that offers of shares may be made to the public in that
Member State at any time under the following exemptions under the Prospectus Regulation: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. to any legal entity which is a qualified
investor as defined under the Prospectus Regulation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. to fewer than 150 natural or legal persons (other than qualified investors as
defined under the Prospectus Regulation), subject to obtaining the prior consent of the underwriters; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. in any other circumstances
falling within Article 1(4) of the Prospectus Regulation, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">provided that no such offer of shares shall require the Company or any
underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation and each person who initially acquires any shares or to whom any offer is made will
be deemed to have represented, acknowledged and agreed to and with each of the underwriters and the Company that it is a &#147;qualified investor&#148; within the meaning of Article 2(e) of the Prospectus Regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of any shares being offered to a financial intermediary as that term is used in Prospectus Regulation, each such financial
intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on <FONT STYLE="white-space:nowrap">a&nbsp;non-discretionary&nbsp;basis</FONT> on behalf of, nor have they
been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares to the public other than their offer or resale in a Member State to qualified investors as so defined or in circumstances
in which the prior consent of the underwriters have been obtained to each such proposed offer or resale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this
provision, the expression an &#147;offer to the public&#148; in relation to shares in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to
enable an investor to decide to purchase or subscribe for any shares, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">References to the Prospectus Regulation includes, in relation to the United Kingdom, the Prospectus Regulation as it forms part of the United
Kingdom domestic law by virtue of the European Union (Withdrawal) Act of 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>United Kingdom.</I><I></I>&nbsp;In addition, in the
United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at persons who are &#147;qualified investors&#148; (as defined in the Prospectus Regulation)&nbsp;(i) who have
professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &#147;Order&#148;) and/or (ii)&nbsp;who are high net worth
companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d)&nbsp;of the Order and/or (iii)&nbsp;to whom it may otherwise be lawfully communicated (all such persons together being referred to as
&#147;relevant persons&#148;) in circumstances which have not resulted and will not result in an offer to the public of the shares in the United Kingdom within the meaning of the Financial Services and Markets Act 2000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any person in the United Kingdom that is not a relevant person should not act or rely on the information included in this document or use it
as basis for taking any action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively by relevant persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Hong Kong.</I><I></I>&nbsp;The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document,
other than (a)&nbsp;to &#147;professional investors&#148; as defined in the Securities and Futures </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Ordinance (Cap. 571 of the Laws of Hong Kong) (the &#147;SFO&#148;) of Hong Kong and any rules made thereunder; or (b)&nbsp;in other circumstances which do not result in the document being a
&#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong (the &#147;CO&#148;), or which do not constitute an offer to the public within the meaning of the CO. No advertisement,
invitation or document relating to the shares has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to
be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to
&#147;professional investors&#148; as defined in the SFO and any rules made thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Singapore.</I><I></I>&nbsp;Each underwriter
has acknowledged that this prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, each underwriter has represented and agreed that it has not offered or sold any shares or caused the shares to be
made the subject of an invitation for subscription or purchase and will not offer or sell any shares or cause the shares to be made the subject of an invitation for subscription or purchase, and has not circulated or distributed, nor will it
circulate or distribute, this prospectus or any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares, whether directly or indirectly, to any person in Singapore other than: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. to an institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act (Chapter 289) of Singapore, as modified or
amended from time to time (the &#147;SFA&#148;)) pursuant to Section&nbsp;274 of the SFA; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. to a relevant person (as defined in
Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified in Section&nbsp;275 of the SFA; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold
investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b. a
trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">securities or securities-based derivatives contracts (each term as defined in Section&nbsp;2(1) of the SFA) of that corporation or the
beneficiaries&#146; rights and interest (however described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under Section&nbsp;275 of the SFA except:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) to an institutional investor or to a relevant person, or to any person arising from an offer referred to in Section&nbsp;275(1A) or
Section&nbsp;276(4)(i)(B) of the SFA; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) where no consideration is or will be given for the transfer; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) where the transfer is by operation of law; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) as specified in Section&nbsp;276(7) of the SFA; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and Securities-based Derivatives
Contracts) Regulations 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Singapore SFA Product Classification &#151; In connection with Section&nbsp;309B of the SFA
and the CMP Regulations 2018, unless otherwise specified before an offer of shares, we have determined, and hereby notify all relevant persons (as defined in Section&nbsp;309A(1) of the SFA), that the shares are &#147;prescribed capital markets
products&#148; (as defined in the CMP Regulations 2018) and Excluded Investment Products (as defined in MAS Notice <FONT STYLE="white-space:nowrap">SFA&nbsp;04-N12:&nbsp;Notice</FONT> on the Sale of Investment Products and MAS <FONT
STYLE="white-space:nowrap">Notice&nbsp;FAA-N16:&nbsp;Notice</FONT> on Recommendations on Investment Products). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Israel.</I><I></I>&nbsp;In the State of Israel this prospectus supplement shall not be regarded as an offer to the public to purchase
shares of common stock and pre-funded warrants under the Israeli Securities Law, 5728 &#150; 1968, which requires a prospectus to be published and authorized by the Israel Securities Authority, if it complies with certain provisions of
Section&nbsp;15 of the Israeli Securities Law, 5728 &#150; 1968, including, inter alia, if: (i)&nbsp;the offer is made, distributed or directed to not more than 35 investors, subject to certain conditions (the &#147;Addressed Investors&#148;); or
(ii)&nbsp;the offer is made, distributed or directed to certain qualified investors defined in the First Addendum of the Israeli Securities Law, 5728 &#150; 1968, subject to certain conditions (the &#147;Qualified Investors&#148;). The Qualified
Investors shall not be taken into account in the count of the Addressed Investors and may be offered to purchase securities in addition to the 35 Addressed Investors. The company has not and will not take any action that would require it to publish
a prospectus in accordance with and subject to the Israeli Securities Law, 5728 &#150; 1968. We have not and will not distribute this prospectus or make, distribute or direct an offer to subscribe for our common stock and pre-funded warrants to any
person within the State of Israel, other than to Qualified Investors and up to 35 Addressed Investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Qualified Investors may have to
submit written evidence that they meet the definitions set out in of the First Addendum to the Israeli Securities Law, 5728 &#150; 1968. In particular, we may request, as a condition to be offered common stock and pre-funded warrants, that Qualified
Investors will each represent, warrant and certify to us and/or to anyone acting on our behalf: (i)&nbsp;that it is an investor falling within one of the categories listed in the First Addendum to the Israeli Securities Law, 5728 &#150; 1968; (ii)
which of the categories listed in the First Addendum to the Israeli Securities Law, 5728 &#150; 1968 regarding Qualified Investors is applicable to it; (iii)&nbsp;that it will abide by all provisions set forth in the Israeli Securities Law, 5728
&#150; 1968 and the regulations promulgated thereunder in connection with the offer to be issued common stock and pre-funded warrants; (iv)&nbsp;that the shares of common stock and pre-funded warrants that it will be issued are, subject to
exemptions available under the Israeli Securities Law, 5728 &#150; 1968: (a) for its own account; (b)&nbsp;for investment purposes only; and (c)&nbsp;not issued with a view to resale within the State of Israel, other than in accordance with the
provisions of the Israeli Securities Law, 5728 &#150; 1968; and (v)&nbsp;that it is willing to provide further evidence of its Qualified Investor status. Addressed Investors may have to submit written evidence in respect of their identity and may
have to sign and submit a declaration containing, inter alia, the Addressed Investor&#146;s name, address and passport number or Israeli identification number. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not authorized and do not authorize the making of any offer of securities through any financial intermediary on our behalf, other than
offers made by the underwriters and their respective affiliates, with a view to the final placement of the securities as contemplated in this document. Accordingly, no purchaser of the shares, other than the underwriters, is authorized to make any
further offer of shares on our behalf or on behalf of the underwriters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx433739_9"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the common stock and pre-funded warrants offered hereby will be passed upon for us by Morgan, Lewis&nbsp;&amp; Bockius LLP,
Boston, Massachusetts. The underwriters are being represented in connection with this offering by Goodwin Procter LLP, New York, New York. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx433739_10"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Kopin Corporation as of December&nbsp;25, 2021 and December&nbsp;26, 2020 and for each of the years
then ended incorporated in this prospectus supplement by reference from the Kopin Corporation Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;25, 2021 have been audited by RSM US LLP, an
independent registered public accounting firm, as stated in their report thereon, incorporated herein by reference, and have been incorporated in this prospectus supplement and the registration statement of which this prospectus supplement forms a
part, in reliance upon such report and upon the authority of such firm as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx433739_11">
</A>WHERE YOU CAN FIND MORE INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus are part of a registration
statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the SEC under the Securities Act. This prospectus supplement and the accompanying prospectus do not contain all of the information included in the registration
statement. We have omitted certain parts of the registration statement in accordance with the rules and regulations of the SEC. For further information, we refer you to the registration statement, including its exhibits and schedules. Statements
contained in this prospectus supplement and the accompanying prospectus about the provisions or contents of any contract, agreement or any other document referred to are not necessarily complete. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings, including the
registration statement and exhibits, are available to the public on the SEC&#146;s website at www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain website at
<I>www.kopin.com</I>. We have not incorporated by reference into this prospectus supplement or the accompanying prospectus the information on our website, and you should not consider any of the information posted on or hyperlinked to our website to
be a part of this prospectus supplement or the accompanying prospectus. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx433739_12"></A>INCORPORATION BY REFERENCE
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; the information we file with the SEC, which means we can disclose important
information to you by referring you to those documents. The information we incorporate by reference is an important part of this prospectus supplement, and certain information that we will later file with the SEC will automatically update and
supersede this information. We incorporate by reference the documents listed below as well as any future filings made with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus supplement until we
sell all of the securities under this prospectus supplement, except that we do not incorporate any document or portion of a document that is &#147;furnished&#148; to the SEC, but not deemed &#147;filed.&#148; The following documents filed with the
SEC are incorporated by reference in this prospectus supplement and the accompanying prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended
December&nbsp;25, 2021, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/771266/000149315222006784/form10-k.htm">March&nbsp;14, 2022</A>; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the fiscal quarter ended
March&nbsp;26, 2022, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0000771266/000149315222012243/form10q.htm">May&nbsp;5, 2022</A>, for the fiscal quarter ended June&nbsp;25, 2022, filed
with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0000771266/000149315222021314/form10-q.htm">August&nbsp;4, 2022</A> and for the fiscal quarter ended September&nbsp;
24, 2022, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/771266/000149315222030943/form10-q.htm">November&nbsp;8, 2022</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/771266/000149315222015459/form8-k.htm">May&nbsp;31,
 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/771266/000149315222025273/form8-k.htm">September&nbsp;
7, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/771266/000149315222035174/form8-k.htm">December&nbsp;
12, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/771266/000149315222035742/form8-k.htm">December&nbsp;
16, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/771266/000149315222036814/form8-k.htm">December&nbsp;
29, 2022</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/771266/000149315223000819/form8-k.htm">January&nbsp;6, 2023</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock, par value $.01 per share contained in <A HREF="http://www.sec.gov/Archives/edgar/data/771266/000077126620000008/kopn-20192812xexx42.htm">Exhibit
 4.2</A> to our Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/771266/000149315221005466/form10-k.htm">December&nbsp;26, 2020</A>, and
including any amendments or reports filed with the SEC for the purpose of updating such description. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will furnish to
you, on written or oral request, a copy of any or all of the documents that have been incorporated by reference, including exhibits to these documents. You may request a copy of these filings at no cost by writing or telephoning our Secretary at the
following address and telephone number: Kopin Corporation, Attn: Investor Relations, 125 North Drive, Westborough, MA 01581, (508) <FONT STYLE="white-space:nowrap">870-5959.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$144,331,326.66 </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g386798g21u69.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt
Securities </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Kopin Corporation (&#147;Kopin&#148; or the &#147;Company&#148;) may offer any combination of the securities described in this prospectus in
one or more offerings from time to time in amounts authorized from time to time. This prospectus may also be used by a selling securityholder of the securities described herein. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Kopin will provide specific terms of the securities, including the offering prices, in supplements to this prospectus. The supplements may
also add, update or change information contained in this prospectus. You should read this prospectus and any supplements carefully before you invest. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Kopin&#146;s common stock is listed on the Nasdaq Capital Market under the symbol &#147;KOPN.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Kopin may offer these securities directly or through underwriters, agents or dealers. The supplements to this prospectus will describe the
terms of any particular plan of distribution, including any underwriting arrangements. The &#147;Plan of Distribution&#148; section beginning on page 6 of this prospectus also provides more information on this topic. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:5%; font-size:12pt; font-family:Times New Roman"><B>See &#147;<A HREF="#tx433739_3">Risk Factors</A>&#148; beginning on page 3 of this prospectus to read about certain factors you should
consider before purchasing any of the securities being offered. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is April 27, 2022. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A NAME="toc"></A><A HREF="#tx433739_1">ABOUT THIS PROSPECTUS</A> </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx433739_2">THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx433739_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx433739_4">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx433739_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx433739_6">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx433739_7">GENERAL DESCRIPTION OF SECURITIES THAT WE MAY SELL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx433739_8">DESCRIPTION OF OUR COMMON STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx433739_9">DESCRIPTION OF OUR PREFERRED STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx433739_10">DESCRIPTION OF OUR WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx433739_11">DESCRIPTION OF OUR DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx433739_12">WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY
REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx433739_13">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx433739_14">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-i- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx433739_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a &#147;shelf&#146; registration statement. Under this shelf registration process, we may sell, at any time and
from time to time, in one or more offerings, any combination of the securities described in this prospectus. The exhibits to our Registration Statement contain the full text of certain contracts and other important documents we have summarized in
this prospectus. Since these summaries may not contain all the information that you may find important in deciding whether to purchase the securities we offer, you should review the full text of these documents. The Registration Statement and the
exhibits can be obtained from the Securities and Exchange Commission (&#147;SEC&#148;) as indicated under the heading &#147;Where You Can Find More Information.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus only provides you with a general description of the securities we may offer. Each time we sell securities, we will provide a
prospectus supplement that contains specific information about the terms of those securities and the terms of that offering. The prospectus supplement may also add, update or change information contained in this prospectus. You should read both this
prospectus and any prospectus supplement together with the additional information described below under the heading &#147;Where You Can Find More Information.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not authorized any dealer, agent or other person to give any information or to make any representation other than those contained or
incorporated by reference into this prospectus and any accompanying prospectus supplement. You must not rely upon any information or representation not contained or incorporated by reference into this prospectus or an accompanying prospectus
supplement. This prospectus and the accompanying prospectus supplement, if any, do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this
prospectus and the accompanying prospectus supplement, if any, constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such
jurisdiction. You should not assume that the information contained in this prospectus and any accompanying prospectus supplement is accurate on any date subsequent to the date set forth on the front of the document or that any information we have
incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus and any accompanying prospectus supplement is delivered or securities are sold on a later date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">References in this prospectus to the terms &#147;the Company,&#148; &#147;Kopin,&#148; &#147;we,&#148; &#147;our&#148; and &#147;us&#148; or
other similar terms mean Kopin Corporation and its subsidiaries, unless the context indicates otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx433739_2"></A>THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Kopin Corporation is a leading developer and provider of high-resolution microdisplays, microdisplay subassemblies and related components for
defense, enterprise, industrial, and consumer products. Our products are used for soldier, avionic, armored vehicle and training&nbsp;&amp; simulation defense applications; industrial, public safety and medical headsets; 3D optical inspection
systems; and consumer augmented reality and virtual reality wearable headsets systems. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated in Delaware in 1984 and are a
leading inventor, developer, manufacturer and seller of technologies, components and systems for the smart headset wearable, military, thermal imager, 3D optical inspection system and training and simulation markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The mailing address of our principal executive offices is 125 North Drive Westborough, MA 01581. Our telephone number is (508) <FONT
STYLE="white-space:nowrap">870-5959</FONT> and our website address is www.kopin.com. The information on our website or any other website is not incorporated by reference in this prospectus and does not constitute a part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx433739_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves risks. You should carefully consider the risks described under &#147;Risk Factors&#148; in our most
recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and in the other documents incorporated by reference into this prospectus (which risk factors are incorporated by reference herein), as well as the other information contained
or incorporated by reference in this prospectus or in any prospectus supplement hereto before making a decision to invest in our securities. See &#147;Where You Can Find More Information,&#148; below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx433739_4"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus, any prospectus supplement and the other documents we have filed with the SEC that are incorporated herein by reference
contain forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended (the &#147;Exchange
Act&#148;), which are subject to the safe harbor created by such sections. Words such as &#147;expects,&#148; &#147;anticipates,&#148; &#147;intends,&#148; &#147;plans,&#148; &#147;believes,&#148; &#147;could,&#148; &#147;would,&#148;
&#147;seeks,&#148; &#147;estimates,&#148; and variations of such words and similar expressions, and the negatives thereof, are intended to identify such forward-looking statements. We caution readers not to place undue reliance on any such
&#147;forward-looking statements,&#148; which speak only as of the date made, and advise readers that these forward-looking statements are not guarantees of future performance and involve certain risks, uncertainties, estimates, and assumptions by
us that are difficult to predict. Various factors, some of which are beyond our control, could cause actual results to differ materially from those expressed in, or implied by, such forward-looking statements. All such forward-looking statements,
whether written or oral, and whether made by us or on our behalf, are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, we disclaim any obligation
to update any forward-looking statements to reflect events or circumstances after the date of this report, except as may otherwise be required by the federal securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have identified the following important factors that could cause actual results to differ materially from those discussed in our
forward-looking statements. Such factors may be in addition to the risks described in Part I, Item 1A. &#147;Risk Factors;&#148; Part II, Item 7. &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations;&#148;
and other parts of our most recent Form <FONT STYLE="white-space:nowrap">10-K.</FONT> These factors include: the extent of the impact of the coronavirus <FONT STYLE="white-space:nowrap">(&#147;COVID-19&#148;)</FONT> pandemic on our business and
operations, and the economic and societal disruptions resulting from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; our belief that the process development efforts on our products used in thermal weapon sight systems is complete and
our expectation that we will increase production rates of our products used in thermal weapon sight systems; our ability to prosecute and defend our proprietary technology aggressively or successfully; our ability to retain personnel with experience
and expertise relevant to our business; our ability to invest in research and development to achieve profitability even during periods when we are not profitable; any disruptions or delays in our supply chains, particularly with respect to
semiconductor components, whether resulting from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or regional or global geopolitical developments or otherwise; our ability to continue to introduce new products in our target markets; our
ability to generate revenue growth and positive cash flow, and reach profitability; the strengthening of the U.S. dollar and its effects on the price of our products in foreign markets; the impact of new regulations and customer demands relating to
conflict minerals; our ability to obtain a competitive advantage in the wearable technologies market through our extensive portfolio of patents, trade secrets and <FONT STYLE="white-space:nowrap">non-patented</FONT>
<FONT STYLE="white-space:nowrap">know-how;</FONT> our ability to grow within our targeted markets; the importance of small form factor displays in the development of defense, consumer, and industrial products such as thermal weapon sights, safety
equipment, virtual and augmented reality gaming, training and simulation products and metrology tools; the suitability of our properties for our needs for the foreseeable future; our expectation not to pay cash dividends for the foreseeable future
and to retain earnings for the development of our businesses; our need to achieve and maintain positive cash flow and profitability, and our expectation that if we do not achieve and maintain positive cash flow and profitability our financial
condition will ultimately be materially adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx433739_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise specified in a prospectus supplement accompanying this prospectus, the net proceeds from the sale of the securities to which
this prospectus relates will be used for general corporate purposes. General corporate purposes may include repayment of debt, acquisitions, additions to working capital, capital expenditures, research and development, and investments in our
subsidiaries. Net proceeds may be temporarily invested prior to use. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx433739_6"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the offered securities in any of the ways described below or in any combination or any other way set forth in an applicable
prospectus supplement from time to time: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through underwriters or dealers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through agents; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">directly to one or more purchasers. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of the securities may be effected from time to time in one or more transactions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price, or prices, which may be changed from time to time; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each prospectus supplement will describe the method of distribution of the securities and any applicable restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement with respect to the securities of a particular series will describe the terms of the offering of the securities,
including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name or names of any underwriters, dealers or agents and the amounts of securities underwritten or purchased
by each of them; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the public offering price of the securities and the proceeds to us and any discounts, commissions or concessions
allowed or reallowed or paid to dealers; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any securities exchanges on which the securities may be listed. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any offering price and any discounts or concessions allowed or reallowed or paid to dealers may be changed from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only the agents or underwriters named in each prospectus supplement are agents or underwriters in connection with the securities being offered
thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may authorize underwriters, dealers or other persons acting as our agents to solicit offers by certain institutions to
purchase securities from us pursuant to delayed delivery contracts providing for payment and delivery on the date stated in each applicable prospectus supplement. Each contract will be for an amount not less than, and the aggregate amount of
securities sold pursuant to such contracts shall not be less nor more than, the respective amounts stated in each applicable prospectus supplement. Institutions with whom the contracts, when authorized, may be made include commercial and savings
banks, insurance companies, pension funds, investment companies, educational and charitable institutions and other institutions, but shall in all cases be subject to our approval. Delayed delivery contracts will be subject only to those conditions
set forth in each applicable prospectus supplement, and each prospectus supplement will set forth any commissions we pay for solicitation of these contracts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Agents, underwriters and other third parties described above may be entitled to indemnification by us against certain civil liabilities,
including liabilities under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), or to contribution from us with respect to payments which the agents, underwriters or other third parties may be required to make in respect
thereof. Agents, underwriters and such other third parties may be customers of, engage in transactions with, or perform services for us in the ordinary course of business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One or more firms, referred to as &#147;remarketing firms,&#148; may also offer or sell the
securities, if a prospectus supplement so indicates, in connection with a remarketing arrangement upon their purchase. Remarketing firms will act as principals for their own accounts or as our agents. These remarketing firms will offer or sell the
securities in accordance with the terms of the securities. Each prospectus supplement will identify and describe any remarketing firm and the terms of its agreement, if any, with us and will describe the remarketing firm&#146;s compensation.
Remarketing firms may be deemed to be underwriters in connection with the securities they remarket. Remarketing firms may be entitled under agreements that may be entered into with us to indemnification by us against certain civil liabilities,
including liabilities under the Securities Act, and may be customers of, engage in transactions with or perform services for us in the ordinary course of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain underwriters may use this prospectus and any accompanying prospectus supplement for offers and sales related to market-making
transactions in the securities. These underwriters may act as principal or agent in these transactions, and the sales will be made at prices related to prevailing market prices at the time of sale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities we offer may be new issues of securities and may have no established trading market. The securities may or may not be listed on
a securities exchange. Underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We can make no assurance as to the liquidity of, or the existence of
trading markets for, any of the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain persons participating in an offering may engage in overallotment, stabilizing
transactions, short covering transactions and penalty bids in accordance with rules and regulations under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). Overallotment involves sales in excess of the offering size,
which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open
market after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a short covering transaction
to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also may sell any of the securities through agents designated by us from time to time. We will name any agent involved in the offer or sale
of these securities and will list commissions payable by us to these agents in the applicable prospectus supplement. These agents will be acting on a best efforts basis to solicit purchases for the period of its appointment, unless stated otherwise
in the applicable prospectuses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell any of the securities directly to purchasers. In this case, we will not engage underwriters
or agents in the offer and sale of these securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may engage in sales deemed to be &#147;at the market offerings&#148; as defined
in Rule 415 promulgated under the Securities Act, including sales made directly on or through the Nasdaq Capital Market, the existing trading market for our common stock, sales made to or through a market maker other than on an exchange or
otherwise, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, and/or any other method permitted by law. The terms of such &#147;at the market offerings&#148; will be set
forth in the applicable prospectus supplement. We may engage an agent to act as a sales agent in such &#147;at the market offerings&#148; on a best efforts basis using commercially reasonable efforts consistent with normal trading and sales
practices, on mutually agreed terms between such agent and us. We will name any agent involved in such &#147;at the market offerings&#148; of securities and will list commissions payable by us to these agents in the applicable prospectus supplement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third
parties in privately negotiated transactions. If the applicable prospectus supplement so indicates, in connection with those derivatives, the third parties may sell securities covered by this prospectus and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the applicable prospectus supplement, including in short sale transactions. If so, the third party may use securities pledged by us or borrowed from us or others to settle those sales or to close
out any related open borrowings of stock, and may use securities received from us in settlement of those derivatives to close out any related open borrowings of stock. The third party in such sale transactions will be an underwriter and, if not
identified in this prospectus, will be named in the applicable prospectus supplement (or a post-effective amendment). In addition, we may otherwise loan or pledge securities to a financial institution or other third party that in turn may sell the
securities short using this prospectus and an applicable prospectus supplement. Such financial institution or other third party may transfer its economic short position to investors in our securities or in connection with a concurrent offering of
other securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The specific terms of any <FONT STYLE="white-space:nowrap">lock-up</FONT> provisions in respect of any given offering
will be described in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters, dealers and agents may engage in transactions with us, or
perform services for us, in the ordinary course of business for which they receive compensation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx433739_7"></A>GENERAL DESCRIPTION OF SECURITIES THAT WE MAY SELL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer and sell, at any time and from time to time: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Shares of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Shares of our preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Warrants to purchase shares of our common stock, preferred stock and/or debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Debt securities consisting of debentures, notes or other evidences of indebtedness; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Any combination of these securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of any securities we offer will be determined at the time of sale. We may issue debt securities that are exchangeable for or
convertible into common stock or any of the other securities that may be sold under this prospectus. When particular securities are offered, a supplement to this prospectus will be filed with the SEC, which will describe the terms of the offering
and sale of the offered securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx433739_8"></A>DESCRIPTION OF OUR COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of 150,000,000 shares of common stock, par value $.01 per share, and 3,000 shares of preferred stock,
par value $.01 per share, which may be issued in one or more series. The following summary of the terms of our common stock is subject to and qualified in its entirety by reference to our charter and <FONT STYLE="white-space:nowrap">by-laws,</FONT>
copies of which are on file with the SEC as exhibits to previous SEC filings. Please refer to &#147;Where You Can Find More Information&#148; below for directions on obtaining these documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;25, 2021, we had 89,988,528 shares of common stock outstanding and no shares of preferred stock outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Dividends.</B> Holders of common stock are entitled to receive proportionately any dividends as may be declared by our Board of Directors
(the &#147;Board&#148;), subject to any preferential dividend rights of any outstanding Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Conversion Rights.</B> The
shares of common stock are not convertible into other securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Sinking Fund Provisions.</B> Our common stock does not have any
sinking fund provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Redemption Provisions.</B> Our common stock has no right to redemption. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Voting Rights.</B> Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of
stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Liquidation Rights.</B> If we are liquidated or dissolved, holders of our common stock will be entitled to receive our assets and funds
available for distribution to common stockholders in proportion to the number of shares they hold. Our common stockholders may not receive any assets or funds until our creditors have been paid in full and the preferential or participating rights of
our preferred stockholders have been satisfied. If we participate in a corporate merger, consolidation, purchase or acquisition of property or stock, or other reorganization, any payments or shares of stock allocated to our common stockholders will
be distributed pro rata to holders of our common stock on a per share basis. If we redeem, repurchase or otherwise acquire for payment any shares of our common stock, we will treat each share of common stock identically. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Preemption Rights.</B> Our common stock has no right to preemption. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Provisions.</B> We are subject to Section&nbsp;203 of the Delaware General Corporation Law, an anti-takeover law. In general,
Section&nbsp;203 prohibits a Delaware corporation from engaging in any &#147;business combination&#148; with any &#147;interested stockholder&#148; for a period of three years following the date the stockholder became an interested stockholder,
unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prior to such date, the Board approved either the business combination or the transaction that resulted in the
stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (a)&nbsp;those shares owned by persons who are
directors and also officers and (b)&nbsp;shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or subsequent to such date, the business combination is approved by the Board and authorized at an annual
meeting or special meeting of stockholders and not by written consent, by the affirmative vote of at least <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the outstanding voting stock that is not owned by the interested stockholder.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 defines a business combination to include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the
interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any
stock of the corporation to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock
of any class or series of the corporation beneficially owned by the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other
financial benefits provided by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an &#147;interested
stockholder&#148; as any entity or person beneficially owning 15% or more of the outstanding voting stock of a corporation, or an affiliate or associate of the corporation and was the owner of 15% or more of the outstanding voting stock of a
corporation at any time within three years prior to the time of determination of interested stockholder status; and any entity or person affiliated with or controlling or controlled by such entity or person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These statutory provisions could delay or frustrate the removal of incumbent directors or a change in control of our company. They could also
discourage, impede, or prevent a merger, tender offer, or proxy contest, even if such event would be favorable to the interests of stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Certificate of Incorporation and Bylaws contain provisions that could have the effect of discouraging potential acquisition proposals or
making a tender offer or delaying or preventing a change in control, including changes a stockholder might consider favorable. In particular, the Certificate of Incorporation and Bylaws, as applicable, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide for advance notice procedures with respect to stockholder proposals and the nomination of candidates for
election as directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that vacancies on our Board may be filled by a majority of directors in office, although less than a
quorum; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide our Board with the ability to amend or repeal our Bylaws, or adopt new bylaws without stockholder
approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide our Board with the ability to increase or decrease the size of the Board without stockholder approval;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that stockholders do not have the right to call a special meeting of stockholders. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such provisions may have the effect of discouraging a third party from acquiring us, even if doing so would be beneficial to our stockholders.
These provisions are intended to enhance the likelihood of continuity and stability in the composition of our Board and in the policies formulated by them, and to discourage some types of transactions that may involve an actual or threatened change
in control of Kopin. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage some tactics that may be used in proxy fights. We believe that the benefits of increased protection of our
potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure Kopin outweigh the disadvantages of discouraging such proposals because, among other things, negotiation of such proposals could
result in an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
improvement of their terms. However, these provisions could have the effect of discouraging others from making tender offers for our shares that could result from actual or rumored takeover
attempts. These provisions also may have the effect of preventing changes in our management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Stock Exchange Listing.</B> Our common
stock is listed on the Nasdaq Capital Market under the symbol &#147;KOPN.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar.</B> The transfer agent
and registrar for our common stock is Computershare Trust Company, N.A. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx433739_9"></A>DESCRIPTION OF OUR PREFERRED STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board may, without further action by our stockholders, from time to time, direct the issuance of shares of preferred stock in series and
may, at the time of issuance, determine the rights, preferences and limitations of each series, including voting rights, dividend rights and redemption and liquidation preferences. Satisfaction of any dividend preferences of outstanding shares of
our preferred stock would reduce the amount of funds available for the payment of dividends on shares of our common stock. Holders of shares of our preferred stock may be entitled to receive a preference payment in the event of any liquidation,
dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of our Company before any payment is made to the holders of shares of our common stock. In some circumstances, the issuance of shares of preferred stock may render more difficult or
tend to discourage a merger, tender offer or proxy contest, the assumption of control by a holder of a large block of our securities or the removal of incumbent management. Upon the affirmative vote of the Board, without stockholder approval, we may
issue shares of preferred stock with voting and conversion rights which could adversely affect the holders of shares of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we offer a specific class or series of preferred stock under this prospectus, we will describe the terms of the preferred stock in the
prospectus supplement for such offering and will file a copy of the certificate establishing the terms of the preferred stock with the SEC. To the extent required, this description will include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title and stated value; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares offered, the liquidation preference per share and the purchase price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dividend rate(s), period(s) and/or payment date(s), or method(s) of calculation for such dividends;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether dividends will be cumulative or <FONT STYLE="white-space:nowrap">non-cumulative</FONT> and, if
cumulative, the date from which dividends will accumulate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the procedures for any auction and remarketing, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions for a sinking fund, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions for redemption, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any listing of the preferred stock on any securities exchange or market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the preferred stock will be convertible into our common stock, and, if applicable, the conversion price
(or how it will be calculated), the conversion period and any other terms of conversion (including any anti-dilution provisions, if any); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price (or
how it will be calculated), the exchange period and any other terms of exchange (including any anti-dilution provisions, if any); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting rights, if any, of the preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of any material U.S. federal income tax considerations applicable to the preferred stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the relative ranking and preferences of the preferred stock as to dividend rights and rights upon liquidation,
dissolution or winding up of the affairs of the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any material limitations on issuance of any class or series of preferred stock ranking senior to or on a parity
with the series of preferred stock as to dividend rights and rights upon liquidation, dissolution or winding up of the Company; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other affirmative, negative or other covenants or contractual rights which might be attendant with the
specific class or series of preferred stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preferred stock offered by this prospectus, when issued, will not
have, or be subject to, any preemptive or similar rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for any series or class of preferred stock will be set forth in each applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx433739_10"></A>DESCRIPTION OF OUR WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section describes the general terms and provisions of our warrants to acquire our securities that we may issue from time to time. The
applicable prospectus supplement will describe the specific terms of the warrants offered through that prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may
issue warrants for the purchase of our debt securities, common stock or preferred stock or other securities issued by us. We may issue warrants independently or together with other securities, and they may be attached to or separate from the other
securities. We will file a copy of the warrant and warrant agreement with the SEC each time we issue a series of warrants, and these warrants and warrant agreements will be incorporated by reference into the Registration Statement of which this
prospectus is a part. A holder of our warrants should refer to the provisions of the applicable warrant agreement and prospectus supplement for more specific information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement will contain, where applicable, the following terms of and other information relating to the warrants:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the specific designation and aggregate number of, and the price at which we will issue, the warrants;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency or currency units in which the offering price, if any, and the exercise price are payable;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation, amount and terms of the securities purchasable upon exercise of the warrants;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the exercise price for shares of our common stock and the number of shares of common stock to be
received upon exercise of the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the exercise price for shares of our preferred stock, the number of shares of preferred stock to
be received upon exercise, and a description of that class or series of our preferred stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the exercise price for our debt securities, the amount of our debt securities to be received upon
exercise, and a description of that series of debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the right to exercise the warrants will begin and the date on which that right will expire or,
if the warrants may not be continuously exercised throughout that period, the specific date or dates on which the warrants may be exercised; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the warrants will be issued in fully registered form or bearer form, in definitive or global form or in
any combination of these forms, although, in any case, the form of a warrant included in a unit will correspond to the form of the unit and of any security included in that unit; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any applicable material U.S. federal income tax consequences; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the identity of the warrant agent for the warrants and of any other depositaries, execution or paying agents,
transfer agents, registrars or other agents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proposed listing, if any, of the warrants or any securities purchasable upon exercise of the warrants on any
securities exchange; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date from and after which the warrants and the common stock, preferred stock or debt
securities will be separately transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">information with respect to book-entry procedures, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any redemption or call provisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the warrants are to be sold separately or with other securities as parts of units; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any additional terms of the warrants, including terms, procedures and limitations relating to the exchange and
exercise of the warrants. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After your warrants expire they will become void. All warrants will be issued in registered
form. The prospectus supplement may provide for the adjustment of the exercise price of the warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Warrants may be exercised at the
appropriate office of the warrant agent or any other office indicated in the applicable prospectus supplement. Before the exercise of warrants, holders will not have any of the rights of holders of the securities purchasable upon exercise and will
not be entitled to payments made to holders of those securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrant agreements may be amended or supplemented without the
consent of the holders of the warrants to which it applies to effect changes that are not inconsistent with the provisions of the warrants and that do not materially and adversely affect the interests of the holders of the warrants. However, any
amendment that materially and adversely alters the rights of the holders of warrants will not be effective unless the holders of at least a majority of the applicable warrants then outstanding approve the amendment. Every holder of an outstanding
warrant at the time any amendment becomes effective, by continuing to hold the warrant, will be bound by the applicable warrant agreement as amended. The prospectus supplement applicable to a particular series of warrants may provide that certain
provisions of the warrants, including the securities for which they may be exercisable, the exercise price and the expiration date, may not be altered without the consent of the holder of each warrant. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
transfer agent and registrar for any warrants will be set forth in the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx433739_11"></A>DESCRIPTION OF OUR DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section describes the general terms and provisions of the debt securities that we may offer under this prospectus, any of which may be
issued as convertible or exchangeable debt securities. We will set forth the particular terms of the debt securities we offer in a prospectus supplement. The extent, if any, to which the following general provisions apply to particular debt
securities will be described in the applicable prospectus supplement. The following description of general terms relating to the debt securities and the indenture under which the debt securities will be issued are summaries only and therefore are
not complete. You should read the indenture and the prospectus supplement regarding any particular issuance of debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will
issue any debt under an indenture to be entered into between us and the trustee identified in the applicable prospectus supplement. The terms of the debt securities will include those stated in the indenture and those made part of the indenture by
reference to the Trust Indenture Act of 1939, as amended (the &#147;Indenture Act&#148;), as in effect on the date of the indenture. We have filed or will file a copy of the form of indenture as an exhibit to the Registration Statement in which this
prospectus is included. The indenture will be subject to and governed by the terms of the Indenture Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise specified in
the applicable prospectus supplement, the debt securities will represent direct, unsecured obligations of the Company and will rank equally with all of our other unsecured indebtedness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following statements relating to the debt securities and the indenture are summaries, qualified in their entirety by reference to the
detailed provisions of the indenture and the final form indenture as may be filed with a future prospectus supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue the debt securities in one or more series with the same or various maturities, at par, at a premium, or at a discount. We will
describe the particular terms of each series of debt securities in a prospectus supplement relating to that series, which we will file with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement will set forth, to the extent required, the following terms of the debt securities in respect of which the
prospectus supplement is delivered: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate principal amount; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issue price or prices, expressed as a percentage of the aggregate principal amount of the debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limit on the aggregate principal amount; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates on which principal is payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interest rate or rates (which may be fixed or variable) or, if applicable, the method used to determine such
rate or rates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates from which interest, if any, will be payable and any regular record date for the interest
payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the place or places where principal and, if applicable, premium and interest, is payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions upon which we may, or the holders may require us to, redeem or repurchase the debt
securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the denominations in which such debt securities may be issuable, if other than denominations of $1,000 or any
integral multiple of that number; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities are to be issuable in the form of certificated securities (as described below) or
global securities (as described below); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the portion of principal amount that will be payable upon declaration of acceleration of the maturity date if
other than the principal amount of the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency of denomination; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation of the currency, currencies or currency units in which payment of principal and, if applicable,
premium and interest, will be made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if payments of principal and, if applicable, premium or interest, on the debt securities are to be made in one or
more currencies or currency units other than the currency of denomination, the manner in which the exchange rate with respect to such payments will be determined; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if amounts of principal and, if applicable, premium and interest may be determined by reference to an index based
on a currency or currencies or by reference to a commodity, commodity index, stock exchange index or financial index, then the manner in which such amounts will be determined; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions, if any, relating to any collateral provided for such debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any addition to or change in the covenants and/or the acceleration provisions described in this prospectus or in
the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any events of default, if not otherwise described below under &#147;Default and Notice;&#148;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions, if any, for conversion into or exchange for shares of our common stock or preferred
stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any depositaries, interest rate calculation agents, exchange rate calculation agents or other agents; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions, if any, upon which the debt securities shall be subordinated in right of payment to
other indebtedness of the Company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue discount debt securities that provide for an amount less than the
stated principal amount to be due and payable upon acceleration of the maturity of such debt securities in accordance with the terms of the indenture. We may also issue debt securities in bearer form, with or without coupons. If we issue discount
debt securities or debt securities in bearer form, we will describe material U.S. federal income tax considerations and other material special considerations which apply to these debt securities in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt securities denominated in or payable in a foreign currency or currencies or a foreign currency unit or units. If we do, we
will describe the restrictions, elections, and general tax considerations relating to the debt securities and the foreign currency or currencies or foreign currency unit or units in the applicable prospectus supplement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exchange and/or Conversion Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may
issue debt securities which can be exchanged for or converted into shares of our common stock or preferred stock. If we do, we will describe the terms of exchange or conversion in the prospectus supplement relating to these debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer and Exchange </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt
securities that will be represented by either: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;book-entry securities,&#148; which means that there will be one or more global securities registered in the
name of a depositary or a nominee of a depositary; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;certificated securities,&#148; which means that they will be represented by a certificate issued in
definitive registered form. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will specify in the prospectus supplement applicable to a particular offering whether
the debt securities offered will be book-entry or certificated securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certificated Debt Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold certificated debt securities issued under an indenture, you may transfer or exchange such debt securities in accordance with the
terms of the indenture. You will not be charged a service charge for any transfer or exchange of certificated debt securities but may be required to pay an amount sufficient to cover any tax or other governmental charge payable in connection with
such transfer or exchange. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The debt securities of a series may be issued in the form of one or more global securities that will be deposited with a depositary or its
nominees identified in the prospectus supplement relating to the debt securities. In such a case, one or more global securities will be issued in a denomination or aggregate denominations equal to the portion of the aggregate principal amount of
outstanding debt securities of the series to be represented by such global security or securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless and until it is exchanged in
whole or in part for debt securities in definitive registered form, a global security may not be registered for transfer or exchange except as a whole by the depositary for such global security to a nominee of the depositary and except in the
circumstances described in the prospectus supplement relating to the debt securities. The specific terms of the depositary arrangement with respect to a series of debt securities will be described in the prospectus supplement relating to such
series. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Protection in the Event of Change of Control </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any indenture that governs our debt securities covered by this prospectus may not have any covenant or other provision providing for a put or
increased interest or otherwise that would afford holders of our debt securities additional protection in the event of a recapitalization transaction, a change of control of the Company, or a highly leveraged transaction. If we offer any covenants
or provisions of this type with respect to any debt securities covered by this prospectus, we will describe them in the applicable prospectus supplement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Covenants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in
this prospectus or the applicable prospectus supplement, our debt securities may not have the benefit of any covenant that limits or restricts our business or operations, the pledging of our assets or the incurrence by us of indebtedness. We will
describe in the applicable prospectus supplement any material covenants in respect of a series of debt securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger and Sale of
Assets </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may agree in any indenture that governs the debt securities of any series covered by this prospectus that we will not
consolidate with or merge into any other person or convey, transfer, sell or lease our properties and assets substantially as an entirety to any person, unless such person and such proposed transaction meets various criteria, which we will describe
in detail in the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Defaults and Notice </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The debt securities of any series will contain events of default to be specified in the applicable prospectus supplement, which may include,
without limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to pay the principal of, or premium or make-whole amount, if any, on any debt security of such series
when due and payable (whether at maturity, by call for redemption, through any mandatory sinking fund, by redemption at the option of the holder, by declaration or acceleration or otherwise); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to make a payment of any interest on any debt security of such series when due; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to perform or observe any other covenants or agreements in the indenture with respect to the debt
securities of such series; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain events relating to our bankruptcy, insolvency or reorganization; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain cross defaults, if and as applicable. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default with respect to debt securities of any series shall occur and be continuing, we may agree that the trustee or the
holders of at least 25% in aggregate principal amount of the then outstanding debt securities of such series may declare the principal amount (or, if the debt securities of such series are issued at an original issue discount, such portion of the
principal amount as may be specified in the terms of the debt securities of such series) of all debt securities of such series or such other amount or amounts as the debt securities or supplemental indenture with respect to such series may provide,
to be due and payable immediately. Any provisions pertaining to events of default and any remedies associated therewith will be described in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any indenture that governs our debt securities covered by this prospectus may require that the trustee under such indenture shall, within 90
days after the occurrence of a default, give to holders of debt securities of any series notice of all uncured defaults with respect to such series known to it. However, in the case of a default that results from the failure to make any payment of
the principal of, premium or make-whole amount, if any, or interest on the debt securities of any series, or in the payment of any mandatory sinking fund installment with respect to debt securities of such series, if any, the trustee may withhold
such notice if it in good faith determines that the withholding of such notice is in the interest of the holders of debt securities of such series. Any terms and provisions relating to the foregoing types of provisions will be described in further
detail in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any indenture that governs our debt securities covered by this prospectus will contain a
provision entitling the trustee to be indemnified by holders of debt securities before proceeding to exercise any trust or power under the indenture at the request of such holders. Any such indenture may provide that the holders of at least a
majority in aggregate principal amount of the then outstanding debt securities of any series may direct the time, method and place of conducting any proceedings for any remedy available to the trustee, or of exercising any trust or power conferred
upon the trustee with respect to the debt securities of such series. However, the trustee under any such indenture may decline to follow any such direction if, among other reasons, the trustee determines in good faith that the actions or proceedings
as directed may not lawfully be taken, would involve the trustee in personal liability or would be unduly prejudicial to the holders of the debt securities of such series not joining in such direction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any indenture that governs our debt securities covered by this prospectus may endow the holders of such debt securities to institute a
proceeding with respect to such indenture, subject to certain conditions, which will be specified in the applicable prospectus supplement and which may include, that the holders of at least a majority in aggregate principal amount of the debt
securities of such series then outstanding make a written request upon the trustee to exercise its power under the indenture, indemnify the trustee and afford the trustee reasonable opportunity to act. Even so, such holders may have an absolute
right to receipt of the principal of, premium or make-whole amount, if any, and interest when due, to require conversion or exchange of debt </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securities if such indenture provides for convertibility or exchangeability at the option of the holder and to institute suit for the enforcement of such rights. Any terms and provisions relating
to the foregoing types of provisions will be described in further detail in the applicable prospectus supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification of the Indenture
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the trustee may modify any indenture that governs our debt securities of any series covered by this prospectus with or without
the consent of the holders of such debt securities, under certain circumstances to be described in a prospectus supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Defeasance; Satisfaction
and Discharge </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement will outline the conditions under which we may elect to have certain of our obligations under
the indenture discharged and under which the indenture obligations will be deemed to be satisfied. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regarding the Trustee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will identify the trustee and any relationship that we may have with such trustee, with respect to any series of debt securities, in the
prospectus supplement relating to the applicable debt securities. You should note that if the trustee becomes a creditor of the Company, the indenture and the Indenture Act limit the rights of the trustee to obtain payment of claims in certain
cases, or to realize on certain property received in respect of any such claim, as security or otherwise. The trustee and its affiliates may engage in, and will be permitted to continue to engage in, other transactions with us and our affiliates.
If, however, the trustee acquires any &#147;conflicting interest&#148; within the meaning of the Indenture Act, it must eliminate such conflict or resign. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The law governing the
indenture and the debt securities will be identified in the prospectus supplement relating to the applicable indenture and debt securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx433739_12"></A>WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY REFERENCE
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website at
www.sec.gov that contains reports, statements and other information about issuers, such as us, who file electronically with the SEC. We maintain a website at www.kopin.com. However, the information on our website is not incorporated by reference
into this prospectus and any prospectus supplement and you should not consider it a part of this prospectus or any accompanying prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; into this prospectus the information in other documents that we file with it. This
means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be a part of this prospectus, and information in documents that we file later with the SEC will
automatically update and supersede information contained in documents filed earlier with the SEC or contained in this prospectus. We incorporate by reference into this prospectus the documents listed below; provided, however, that we are not
incorporating, in each case, any documents or information deemed to have been furnished and not filed in accordance with SEC rules: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/771266/000149315222006784/form10-k.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended December&nbsp;25, 2021 filed on March&nbsp;14, 2022; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock, par value $.01 per share contained in our Current report on <A HREF="http://www.sec.gov/Archives/edgar/data/771266/000077126617000023/kopn-8xkdescriptionofcommo.htm">
<FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT></A> filed on March&nbsp;31, 2017. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All reports and other documents
we subsequently file pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of this offering, including all such documents we may file with the SEC after the date of this initial registration statement and
prior to the effectiveness of this registration statement, but excluding any information furnished to and not filed with, the SEC, will also be incorporated by reference into this prospectus and deemed to be part of this prospectus from the date of
the filing of such reports and documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may obtain a copy of any or all of the documents referred to above which may have been or
may be incorporated by reference into this prospectus, except for exhibits to those documents (unless the exhibits are specifically incorporated by reference into those documents) at no cost to you by contacting us at the following address and
telephone number: Kopin Corporation, Attn: Investor Relations, 125 North Drive Westborough, MA&nbsp;01581, telephone: (508) <FONT STYLE="white-space:nowrap">870-5959.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx433739_13"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise specified in the prospectus supplement accompanying this prospectus, Morgan, Lewis&nbsp;&amp; Bockius LLP will provide
opinions regarding certain legal matters. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx433739_14"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Kopin Corporation as of December&nbsp;25, 2021 and December&nbsp;26, 2020 and for each of the years
then ended incorporated in this Prospectus by reference from the Kopin Corporation Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;25, 2021 have been audited by RSM US LLP, an independent
registered public accounting firm, as stated in their report thereon, incorporated herein by reference, and have been incorporated in this Prospectus and Registration Statement in reliance upon such report and upon the authority of such firm as
experts in accounting and auditing. </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g386798g43k46.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Shares of Common Stock </B></P>
<P STYLE="margin-top:28pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to Purchase &nbsp;&nbsp;&nbsp;&nbsp; Shares of Common Stock </B></P>
<P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:28pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Stifel </B></P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:44pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>January&nbsp;&nbsp;&nbsp;&nbsp;, 2023 </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g386798g21u69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g386798g21u69.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[18&4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %>J^5A X0DE-! 0      %D< @   @  ' )0  AR<C,Y,#DX,AP"!0!
M36EC<F]S;V9T(%=O<F0@+2 Q,#DV.3%?7S(P-#(R.#$V-78R7TMO<&EN("T@
M4RTS(%!/4R!!32!-3$(@1')A9@ X0DE-!"4      ! BM7J,E$]D^P=NB%D0
M6L4O.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  0.__C4  @ !.$))300F       .
M             #^    X0DE-! T       0   !:.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         !
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,]    !@
M            ,P   /H    $ %, 5  P #,    !
M      $              /H    S                      $
M                $     $       !N=6QL     @    9B;W5N9'-/8FIC
M     0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N
M9P          0G1O;6QO;F<    S     %)G:'1L;VYG    ^@    9S;&EC
M97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L
M;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%
M4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%
M4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG    ,P    !29VAT;&]N9P   /H    #=7)L5$585     $       !N
M=6QL5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     0X0DE-! P     "V<    !    H
M "$   '@   ]X   "TL &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( "$ H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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M$0 _ +'J?63J77L[!Z?G7A]=U[D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M-C=2\!DE)SA#T4=38V1F<G-U=X6CLM+A\?_$ !P!  ,  P$! 0
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M>H0P[&DW).RAIEQMU ;+D2,GK())RO\ /AN\5<U&GTF#(R4?[^? F!RF[?\
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MV)P9$KTE8+21W';BM.&N7XV6LOE4X&CJ/-REV#@/KN[]P_32=,^5>%6:J(L
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MR;BKA('@9E)_P.?KY.?/$C\5E1#FF/SIY1RN W?<]1_.F*4X=$*H:3RA-PX
M ;RAPW0;=0;8,4KRK_VJ?[CPLL,#"-G.W^]OYO\ /O\ H;8Q_A#F?W_7BO.#
M;C*<N#=(B3'HWC1@YVM^X8F7BDE\P1V-R(&A;_"AO_#U&*<ZA;:;QL7;[HON
M):AKJ%@:KP:Y!EU!AMQQ-OW)2+DN*AB+4',=+2*G&IL)5.<4KH]=J2G/44@E
MM.SC3X]8J%%6L)FI)03+IM]X&!<-K;KN[:8'YR@S4&FIJ,-+RY!90]38GH&8
M7%FU=\6CY6V^)[:'K:S3+JEE&CVIDJ%3KQRVE3=$JS8$.C7$V1TK;3&<<>CU
M%"24JC*>?*26 2,\5,F_;E+3.R]X\HX8%RUGM[=7L!CJY S,:-/&#'#09FX)
M;30-T9S?]VCRM!KE.N.DTZLT>:S4(%0C,284N*XV[&?BR&?69?:<;4I"V7F7
M I"TJ.1@_,B/H\O$E(T67B@B+ )!2>WL^NO7N!BH8$>%-08<Q"5S(6 7>YM_
M/OZ8I)S-HC\[9!N#8C(4MU5D>H$(&5A+%9IDAX #N,,MYQCP2>"/)T1*<P4K
MQ!83:'T%W;>W<F^^!_-B"JBSX#OX9 ;H&^C[6>WKA%'1.9#I^L.F$R<$IAL7
MU;2GRH H"#5HR4J<]DA#H .<?QXM?,Z(D?+TUX()_0]MBP<[Z:MKO=QB5LO\
ML*LP^8G^U,05:W( 8V/;WOKC)'V>ZQ*MBAOLJ0ZP]2(#K:TGL4JB-8(P<$?+
MM[Y^?$$3,,IF(H5^(1%_/F+GU?KVQ8TLH*@0B+#PT-IH4ANWYX[KUW!V"NP[
M#\AXXQ8SX^66I/PSQ5C/0MSJ]@ /O9^6!^6/'CCX'*PD!GW#OIJ&W[OLVK8\
MK+(6=?*0VO\ -\8^WF.5.'4]YNNKL)Q+C+5U&*LMG*?6890%Y(SW!5A7T['Z
MV[PK@1(&5Y(1!Y5PSR\SO< Z=[_3IB2\_J$2N11#/FYEBP'73N>FAN&PRQR(
M*=+:V>RIKREAB=J%<'PZ\=B&(U/2XL$> "K'MDX\\3YQACPHN9U(18HA@&UW
M38[=02YWP[>&4)2*$@J.I20&_9ON=/W8$#S[%C^F5;P&<G2:A#N.^!<%=S_A
M_P#P<-/@8E1R_,KNR)J9L[.0F4!>]V!/LIF8G"VXMD*K, :M#2'W%@>G=OIV
M SM-]K&ONL%N"[]-M-;CNJ@B?+IIJ-,BN/1S*AM1%OMI4G*2MLR@@CN1TI3C
MP.&57,RY:ILS$DZG,P$3"AXC*"2H$%PE1(<\H) %M]KX$*92ZU/2B#3Y>(I'
MBEUI"F8W+%.S$N'T9]L2&SR^]X+ZVVVM#;U6X5@(#M.<1W]UE2AV&/W'./''
M$@\1,I00D)FH*0$@.D)!8!@YM;6UF';&Y$RIF@Q/[+%4S\K@E@3T</:WU-W&
M+A[;N3/N<U3NND#5:WOYMK%;EQ7JS,J#Z$5>73BXV[(CT]A <7Z[K68I>6$X
M02?R$<S<6Z5"E9B5I401%:VT?9KZ !R>C/W):)PZJ4>9@1I]!0EPY4"03;8]
M; :D/9FPXYI#I;;&C>G-M:=6C 9IE!M:C1:13XC20 F/$82RE:C@=3J_3+CJ
MR>I2B5').>)>J,]$J,]$FHA),91+>KE@^_1]O?% T^1AT^2$K#2!R)L;/S-J
M?ELX';3"-W->&-]>MWUN!!_^BV/[<9_?GBR>$@']$I,$"T)?T&OUQ,G$8?\
M,LRX_5)O[_+#"'(/0G^B57,Y.-0Z\K(\?K)_/_CQ]9_XO?WJC?\ @G\AAO\
M#0_U&D@7YF#^P^OJUQTQ(?.Y(5LNN4*'BN4DY\=O63Y_O\8XUN$H/]+90D!N
M588AR&T;KMW.-WB,.;+T<,-W.^A/[@!T?"]')JZ5;Y+!4H=0,&L(*3CP8B\=
MOWCOW&,^_#YXR#Q,KS2@'$.'":P_S!Q=MN@W;IA.\+;5LI4Q<L!J &]/7]Q?
M!?N>OM4_2_36B;A[3I"':]IRZ(=R*BM%3LRVIRT!UUX(3E::=)#4E2E$=#2'
ML=E$%1<(\S_9=1$A'41 F5<H!59+V! )\I<C0!@3IAC\2*"9J5^/A('W0\Q
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M'3[9QY!^9[CA9X86$;N=J K?[J DDG-FV0<?G!F@=O&,^P^6>*\X-A\I)?\
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M&TKGU,L."'%92#ZBW7GBD!"$]AW(X[F7Z1,5>IRLM A+7XD0"*0">5+CS/H
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M\,,@ =!?2VV/P80A:EI; 5CN!@>V!G&/;L?IV[#QY4"7(?F]=?5^WMCV-A8
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MJA0X$2X/G$, @W9W!##H-FQ)V8Y.8H=6^&A B$(ZU<[7*>>SJ8$CZN'OB?\
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M=_'C\O:J^!Z_ZEFDZ\L68W>X@(/L;:ZV))Q.O%% ->AEA_TI<$M_FBJ2?9@
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MB4EK/#OX/9L33JG]FSBB9>9 2D+42A*MR$DD))<W8&P))?"HXA9:1,0%3\(
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M<  #_*C3X8!(![C2_.3U'OY[^>,<+BGF;Q$_=TS>WP\SL''_ 'G88\GA_05
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M.W3PIXT:+&BJBQ5JB1%'F4M:B5$J )N2X!Z##0@0D0$>'"2$)3Y0$@)L PT
MOWQW[4='0D94 "#@=('8#V"0 ._@ 8]N-8?XA%M=/<XS;-@1F]OEBZ![N=6(
M.J&I-UZN46OT^U&K?9AV17[.IE'7"IT^?,9<=8KEA7'.5)<=E+2\I%10RIM"
M$ML-DN*<9V3,[5?+<DJ%3X4DM*XIYC,PYB(?,D<S>'-00Q%F8V &%_FS*5-K
M$XB8FHTXA?@PRT")+H!NX\RY:)$#%R&B!G+-BV&RG:YI_M*T>1I9IQ5[QK5O
MJN6N7 9E[5"C5*L_&U1$7XAH2:%;]MPOA6Q 9#"/L_U4!3G6\X5)*!G-]<G:
M_5IFHSR8 F%0H)5X"8B$'E "7"XL11Y19)YW  &F.]EBCRM%IL"4DU1C",2*
M?OE(6H>9F!3#0&;JD_GBX7I)6AMPDA2DI4<8 RI/4<#'@'P/8<#*"5)!.I&V
M"-0 ) T!('H"V.7T$=_O+^]Y[C_\?H/.?''K'S&U;*0VL9404D=R/![8';P!
MV ^7'[&-7X@-K?F< _W-<HO;9N#UHNW5B\[SUMIMQW;,5,J42V+EL:#1F70E
M*>F'&J>G%9FMMD?LOU&21^RI/#6RUQ$KE"I<.0E(%.B0$EDF8A3:H@!>P5!G
M8 #-9D^KX6^8\ETFJSL6=F8DXF-RW\)<NE)NE@0J56H@.P\UAOB]&R7:?ISM
M&TMFZ>::UB]*Q1)%<EUM<F]JE1:G5!+FJ"74)D42WK=C".D)_#08:E@D];J^
MV S-=9FZY4ESLVF##C<K-+B*E!8 W$:+'4==U-@KRO2Y:ETV'"EC$*#$((B%
M"G:SGEAHN=_RQWV\+;38FZK2&H:8:AU6[:/0)<R-*=EV;4*33JN%QG.IM"'Z
MW0KAA)02/O\ _-Y61V"P,8PY8K<W0ZG#GY-$!<>$Q2)A,1<-P=T(BPB?3F;'
MW,5,@52G1(,PJ*A#E_!,-)-R+B)#B)__ %Q0_:ERH-NFV#62@ZKV!>.M%6N*
MF1Y+;$*[KDLJ?1%ID(])9>C4;3R@3E*"3E);J+8ZNZ@KQP<9HX@5NO4N9E9V
M!3DH6M!*I>!,0EAVL'FUPVO;F0H]\!^7<J4VDU!$>6B3:EMS-%7 *79](4O"
M+7Z]-P#@U:600G*UG  _9\#L!^K].%.+E0-V.]^O7]S##0^F(\U.L&V-2;(N
MJQ;O@"JVU=-&G4&LP'"@IDTVJLF%,:'6AQ"5+8>6$KZ"4J"3@@$'9EIR/3X\
M*9EE<L6'%AE)=8'XQ9D*06:S/<:OC3FY>%/2T:7CH!AK000+'\)N">9CO;<^
MC *5R(=H+;RTHU!W&I0'FDI1^F&FZDI2Z5E0'7I(I1]@DE1*0 D$)[</"#Q:
MS1!A(@I@TLI0@0[P)UUA Y05M/@%1 =1  ))8#0*B/P[H,2*8GB3Z"H\S(BR
MS)Y@5\J2J44I@2P=1(  <F^+X[&N7AHIM$.J)TUN74^M?SABR36A>]:M2IB)
M^B2KP3312OL*RK;] /"Y)WQHEF;ZA:BECX8H>^(#<VYUJ]>,A$G8<FE4O\4E
M @0YA :)\,5<PB346[H#<O+N[V8KRWE>G4E4ZB5B313&AR2E^*N"HN@3+$<D
*"'KSEW?9FN__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g386798g43k01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g386798g43k01.jpg
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MYB,R5G%R@9>R&B8T0F>1I]135%AHDY26HZC1TM/6Y_#_Q  = 0 " @,! 0$
M           '" 8)  ,%! $"_\0 7!$  @(! P(" PD&#PL*!P   0(#! 4
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MQLK@%BL259&"@@%BJ@G@$@$\<<D#Y=:Y),I"H:9[\2D](:1K"*6()"@L0"2
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M.*9F9H$+,S&H2S,22222222>=)+;W1N9;5E5W%G55;$RJJY?(!542,  !8X
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M/2E"\F-H6\D.0TU>91TF/[C\.MM[@@DZ:4&,OE28;]"%('63U@V(8PD-I">
MXD7S2O(CFB/# &?4+@;(.F7,5YPCE".386^BRPQ[M1J916,EX]PBD]AK#"N5
M4T3NH6?B7+.5C%E$47 -G1$7C=J]2<M47MVYG\=NC"T,[BY#)3OP^8@;@2PR
M*QCGK3J"0L]>97BE4%EZD+(S(RLRGYG$7<#D[>*OH$LU).ABO)CE0@/%-$Q
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M!$1%+.[L0%554%F9B0 H!))  YT2'=(U9W941%+.[L%554<LS,2 J@ DDD
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MZRD(\%W***#QS$MD;PQV]\!5S5 B.1ON&0IEPTM"\BJ9JTG'!*_&$D$A"^=
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M*]GXXJ;8 YU"'54#Z*1MBMX/>%V[-F;IM9;.04HJ<N%MT4:O=CL2&Q-<Q\R
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M59 .EU)2'<.%L;?S-_$6>2].=ECD(X$]=P)*\Z_)Q-"R.0.>EB4/QE($>O\
M]_J^K:1:XVLVS6:E)\U7\?/T7_>+:)_"C\1_*?[/K9\'OQS\G_W^L^:K^/GZ
M+_O%MGPH_$?RG^SZSX/?CGY/_O\ 6?-5_'S]%_WBVSX4?B/Y3_9]9\'OQS\G
M_P!_K/FJ_CY^B_[Q;9\*/Q'\I_L^L^#WXY^3_P"_UGS5?Q\_1?\ >+;/A1^(
M_E/]GUGP>_'/R?\ W^L^:K^/GZ+_ +Q;9\*/Q'\I_L^L^#WXY^3_ ._U>;N#
ML,?)OJCRQ,>LGC/>X"EHWM_!_#NESY$QVZZW6\5?<_#M>GT^D3CS\W4#EY3
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IX4_(?[9K/L9W^FO_ &;_ +^[9^BA_ ?_ 'G_ ,/UGP%_A3\A_MFO_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g386798g43k46.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g386798g43k46.jpg
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MQ:E9!'?$,-;>F[:]>**""#<N<A@@AC6*&&*/)V4CBBB0*D<<: *B(H55 50
M -%CM662;;&WIII'FFEPF+DEEE=I)))'I0,[R.Y+.[L2S,Q+,2222=1_S[YN
MT/@OHN4V38O*3-YF_-06J*"LC+95QM^1_&WDA+2DDCUB 2XU)VJ51X$B@^@
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M5'NQ5,E3FL$_JCKK+(?B<GPU!_9C92KO?"M(0J3-;K<D\>KL4;,4('ZWF:-
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M;71I:3RT]]5R9^4%N;Z1K)U9MM#VI;7_ &=PG\,JZ!C<?MASWTSE/OT^F O
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2+J'=>JW][;_]"?W<=9K-?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
